Sagimet Biosciences Files 8-K/A Amendment
Ticker: SGMT · Form: 8-K/A · Filed: Jun 13, 2024 · CIK: 1400118
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Sagimet Biosciences filed an amendment to its 8-K, adding financial statements and exhibits.
AI Summary
Sagimet Biosciences Inc. filed an amendment (8-K/A) on June 13, 2024, to its previous report dated June 5, 2024. This amendment primarily concerns the filing of financial statements and exhibits. The company, formerly known as 3-V Biosciences, Inc., is incorporated in Delaware and its principal executive offices are located in San Mateo, California.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition of information, specifically related to financial statements and exhibits, which are crucial for investors to understand the company's financial health.
Risk Assessment
Risk Level: low — This is a procedural amendment to a previous filing, primarily for adding exhibits and financial statements, and does not appear to contain new material business events.
Key Players & Entities
- Sagimet Biosciences Inc. (company) — Registrant
- 3-V Biosciences, Inc. (company) — Former company name
- June 5, 2024 (date) — Date of earliest event reported
- June 13, 2024 (date) — Date of report filing
- San Mateo, California (location) — Principal executive offices location
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previous report, specifically to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 5, 2024.
What is the filing date of this amendment?
This amendment was filed on June 13, 2024.
What was Sagimet Biosciences Inc. formerly known as?
Sagimet Biosciences Inc. was formerly known as 3-V Biosciences, Inc.
Where are Sagimet Biosciences Inc.'s principal executive offices located?
Sagimet Biosciences Inc.'s principal executive offices are located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-13 06:07:21
Key Financial Figures
- $0.0001 — ich registered Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq G
Filing Documents
- tm2417159d1_8ka.htm (8-K/A) — 30KB
- tm2417159d1_ex99-1.htm (EX-99.1) — 35KB
- tm2417159d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-24-071014.txt ( ) — 263KB
- sgmt-20240605.xsd (EX-101.SCH) — 3KB
- sgmt-20240605_lab.xml (EX-101.LAB) — 33KB
- sgmt-20240605_pre.xml (EX-101.PRE) — 22KB
- tm2417159d1_8ka_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On June 6, 2024, the Company filed a Current Report on Form 8-K announcing that the Company issued a press release regarding its presentation of positive data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients at the European Association for the Study of the Liver (EASL) Congress 2024. The press release was revised to correct typographical errors as discussed in the Explanatory Note and a copy of the revised press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Revised Press Release of Sagimet Biosciences Inc., dated June 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sagimet Biosciences Inc. Date: June 13, 2024 By: /s/ David Happel David Happel Chief Executive Officer